Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers
October 03, 2023 08:01 ET | Ocean Biomedical, Inc.
Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on Pioneering Anti-CHI3L1 Discoveries Providence, RI, Oct. 03, 2023 (GLOBE...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Malaria Vaccine Patent Granted in Brazil, the 25th Patent Allowance for Programs in Infectious Disease, Cancer and Fibrosis
June 08, 2023 08:01 ET | Ocean Biomedical, Inc.
Patent for breakthrough approach to disrupting the malaria parasite’s life cycle adds to a growing global patent portfolio, with 25 patents issued and an additional 38 patents pending. ...